Ignite Creation Date:
2024-05-05 @ 10:27 PM
Last Modification Date:
2024-10-26 @ 10:19 AM
Study NCT ID:
NCT01117987
Status:
TERMINATED
Last Update Posted:
2015-08-13
First Post:
2010-05-03
Brief Title:
Extension to QTI571A2301 to Evaluate the Long-term Safety Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension PAH
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
An Extension to QTI571A2301 to Evaluate the Long-term Safety Tolerability and Efficacy of Oral QTI571 Imatinib in the Treatment of Severe Pulmonary Arterial Hypertension IMPRES Extension
Status:
TERMINATED
Status Verified Date:
2015-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Novartis discontinued the development of imatinib in PAH due to requirement of regulatory authorities for additional data to secure marketing approval in PAH
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IMPRES Extn
Brief Summary:
This is a multinational multi center extension study This study will provide data on the long-term safety tolerability and efficacy of imatinib in the treatment of severe pulmonary arterial hypertension
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2009-018167-26 | None | None | None |